I am/have/had
I am looking for
Advanced Filters
Found 1 clinical trials
CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma
The purpose of this study is to determine if it is possible to give CPI-613 with the drug Bendamustine for 2 days every 28 days without causing severe side effects. In addition, this study will also test the safety of CPI-613 when given in combination with Bendamustine.
psoralen
systemic therapy
liver metastasis
bendamustine
lymphoma
- 0 views
- 19 Feb, 2024